Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
详细信息 查看全文
- 作者：Thierry Poynard (1)
Pascal Lebray (1)
Patrick Ingiliz (1)
Anne Varaut (1)
Brigitte Varsat (2)
Yen Ngo (1)
Pascal Norha (1)
Mona Munteanu (3)
Fabienne Drane (3)
Djamila Messous (4)
Fran?oise Imbert Bismut (4)
Jean Pierre Carrau (2)
Julien Massard (1)
Vlad Ratziu (1)
Jean Pierre Giordanella (2) - 刊名：BMC Gastroenterology
- 出版年：2010
- 出版时间：December 2010
- 年：2010
- 卷：10
- 期：1
- 全文大小：746KB
- 参考文献：1. Hakama M, Coleman MP, Alexe DM, Auvinen A: Cancer screening: evidence and practice in Europe 2008. / Eur J Cancer 2008, 44:1404-3. CrossRef
2. World Health Organization: Revised global burden of disease 2002 estimates. [http://www.who.int/healthinfo/global_burden_disease/en/index.html]
3. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P: A comparison of fibrosis progression in chronic liver diseases. / J Hepatol 2003, 38:257-5. CrossRef
4. Manning DS, Afdhal NH: Diagnosis and quantitation of fibrosis. / Gastroenterology 2008, 134:1670-1. CrossRef
5. Poynard T, Muntenau M, Morra R, Ngo Y, Imbert-Bismut F, Thabut D, Messous D, Massard J, Lebray P, Moussalli J, Benhamou Y, Ratziu V: Methodological aspects for the interpretation of liver fibrosis non-invasive biomarkers: a 2008 update. / Gastroenterol Clin Biol 2008, 32:8-1. CrossRef
6. Halfon P, Munteanu M, Poynard T: FibroTest-ActiTest as a non-invasive marker of liver ?brosis. / Gastroenterol Clin Biol 2008, 32:22-8. CrossRef
7. Ngo Y, Benhamou Y, Thibault V, Ingiliz P, Munteanu M, Lebray P, Thabut D, Morra R, Messous D, Charlotte F, Imbert-Bismut F, Bonnefont-Rousselot D, Moussalli J, Ratziu V, Poynard T: An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (Fibrotest-Actitest) and viral load. / PlosOne 2008, 3:e2573.
8. Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A, Barri-Ova N, Dauvois B, Prévot S, Ngo Y, Munteanu M, Balian A, Njiké-Nakseu M, Perlemuter G, Poynard T: Diagnostic and prognostic values of non-invasive biomarkers of fibrosis in patients with alcoholic liver disease. / Hepatology 2009, 49:97-05. CrossRef
9. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E: Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. / Gastroenterology 2008, 134:960-4. CrossRef
10. Poynard T, Ingiliz P, Elkrief L, Munteanu M, Lebray P, Morra R, Messous D, Bismut FI, Roulot D, Benhamou Y, Thabut D, Ratziu V: Concordance in a world without a gold standard: A new non-invasive methodology for improving accuracy of fibrosis markers. / PlosOne 2008, 3:e3857.
11. Ratziu V, Giral P, Munteanu M, Messous D, Mercadier A, Bernard M, Morra R, Imbert-Bismut F, Bruckert E, Poynard T: Screening for liver disease using non-invasive biomarkers (FibroTest-SteatoTest-NashTest-FibroSURE) in patients with hyperlipidaemia. / Aliment Pharmacol Ther 2007, 25:207-8. CrossRef
12. Jacqueminet S, Lebray P, Morra R, Munteanu M, Devers L, Messous D, Bernard M, Hartemann-Heurtier A, Imbert-Bismut F, Ratziu V, Grimaldi A, Poynard T: Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. / Clin Gastroenterol Hepatol 2008, 6:828-1. CrossRef
13. Friedman SL, Bansal MB: Reversal of hepatic fibrosis -- fact or fantasy? / Hepatology 2006,43(2 Suppl 1):S82-. CrossRef
14. Poynard T, Calès P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D: Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. / N Engl J Med 1991,30(324):1532-. CrossRef
15. Imbert-Bismut F, Naveau S, Morra R, Munteanu M, Ratziu V, Abella A, Messous D, Thabut D, Benhamou Y, Poynard T: The diagnostic value of combining carbohydrate deficient transferin, fibrosis and steatosis biomarkers for the prediction of excessive alcohol consumption. / Eur J Gastroenterol Hepatol 2009, 21:18-7. CrossRef
16. Becker U, Deis A, S?rensen TI, Gr?nbaek M, Borch-Johnsen K, Müller CF, Schnohr P, Jensen G: Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. / Hepatology 1996, 23:1025-. CrossRef
17. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V: Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. / Gastroenterology 2005, 128:343-0. CrossRef
18. Castéra L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, Couzigou P, de Lédinghen V: Pitfalls of liver stiffness measurement: A 5-year prospective study of 13,369 examinations. / Hepatology 2010, 51:828-5.
19. Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M: Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome. / J Hepatol 2008, 48:606-13. CrossRef
20. Institut de Veille Sanitaire: Prevalence of hepatitis B and hepatitis C in France. [http://www.invs.sante.fr/publications/2006/prevalence_b_c/index.html]
21. French national survey on nutrition and health, ENNS [http://www.invs.sante.fr/publications/2007/nutrition_enns/index.html]
22. Hintze JL: NCSS 2007 User Guide. / Number Cruncher Statistical Systems software NCSS, Kaysville, Utah 2007.
23. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. / Hepatology 2005, 42:44-2. CrossRef
24. Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. / Am J Gastroenterol 2003, 98:960-. CrossRef
25. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, Yueh SK: Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. / J Gastroenterol Hepatol 2007, 22:1482-. CrossRef
26. Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, Bruno S, Mangano C, Polito I, Amato F, Cotichini R, Stroffolini T, Mele A, ACE Collaborating Group: Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. / Hepatology 2005, 41:1151-. CrossRef
27. Poynard T, Benhamou Y, Thabut D, Ratziu V: Liver Biopsy: the best standard... when everything else fails. / J Hepatol 2009, 50:850-. CrossRef
28. Bedossa P, Dargère D, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. / Hepatology 2003, 38:1449-457.
29. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T, LIDO Study Group: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. / Gastroenterology 2005, 128:1898-906. CrossRef
30. Yoneda M, Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, Nozaki Y, Yonemitsu K, Higurashi T, Takahashi H, Kobayashi N, Kirikoshi H, Abe Y, Inamori M, Kubota K, Saito S, Tamano M, Hiraishi H, Maeyama S, Yamaguchi N, Togo S, Nakajima A: Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). / Dig Liver Dis 2008, 40:371-. CrossRef
31. Bell BP, Manos MM, Zaman A, Terrault N, Thomas A, Navarro VJ, Dhotre KB, Murphy RC, Van Ness GR, Stabach N, Robert ME, Bower WA, Bialek SR, Sofair AN: The epidemiology of newly diagnosed chronic liver disease in Gastroenterology. Practices in the united states: results from population-based surveillance. / Am J Gastroenterol 2008, 103:2727-6. CrossRef
32. U.S. Preventive Services Task Force: Guide to clinical preventive services. [http://www.ahrq.gov/clinic/uspstf/uspstopics.htm]
33. Chen JG Parkin DM, Chen QG, / et al.: Screening for liver cancer: results of a randomised, controlled trial in Qidong, China. / J Med Screen 2003, 10:204-. CrossRef
34. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, Zhu YR: Randomized controlled trial of screening for hepatocellular carcinoma. / J Cancer Res Clin Oncol 2004, 131:417-2.
35. Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, Nowacki MP, Butruk E: Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. / N Engl J Med 2006, 355:1863-2. CrossRef
36. Schr?der FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, M??tt?nen L, Bangma CH, Aus G, Villers A, Rebillard X, Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, ERSPC Investigators: Screening and prostate-cancer mortality in a randomized european study. / N Engl J Med 2009, 360:1320-. CrossRef
37. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/10/40/prepub - 作者单位：Thierry Poynard (1)
Pascal Lebray (1)
Patrick Ingiliz (1)
Anne Varaut (1)
Brigitte Varsat (2)
Yen Ngo (1)
Pascal Norha (1)
Mona Munteanu (3)
Fabienne Drane (3)
Djamila Messous (4)
Fran?oise Imbert Bismut (4)
Jean Pierre Carrau (2)
Julien Massard (1)
Vlad Ratziu (1)
Jean Pierre Giordanella (2)
1. APHP-UPMC-Liver Center, Assistance Publique H?pitaux de Paris, Université Pierre et Marie Curie, Paris, France
2. Caisse Primaire Assurance Maladie, Paris, France
3. Biopredictive, Paris, France
4. Biochemistry Unit, Assistance Publique H?pitaux de Paris, Université Pierre et Marie Curie, Paris, France
文摘
Background FibroTest and elastography have been validated as biomarkers of liver fibrosis in the most frequent chronic liver diseases and in the fibrosis screening of patients with diabetes. One challenge was to use them for estimating the prevalence of fibrosis, identifying independent risk factors and to propose screening strategies in the general population. Methods We prospectively studied 7,463 consecutive subjects aged 40 years or older. Subjects with presumed advanced fibrosis (FibroTest greater than 0.48) were re-investigated in a tertiary center. Results The sample characteristics were similar to those of the French population. FibroTest was interpretable in 99.6%. The prevalence of presumed fibrosis was 2.8%, (209/7,463), including cirrhosis in 0.3% (25/7,463); 105/209 (50%) subjects with presumed fibrosis accepted re-investigation. Fibrosis was confirmed in 50, still suspected in 27, indeterminate in 25 and not confirmed with false positive FibroTest or false negative elastography in 3 subjects. False negative rate of FibroTest estimated using elastography was 0.4% (3/766). The attributable causes for confirmed fibrosis were both alcoholic and nonalcoholic fatty liver disease (NAFLD) in 66%, NAFLD in 13%, alcohol in 9%, HCV in 6%, and other in 6%. Factors independently associated (all P < 0.003) with confirmed fibrosis were age, male gender, waist circumference, HCV antibody and alcohol consumption estimated using carbohydrate-deficient transferrin, enabling efficient screening-oriented strategies to be compared and proposed. Conclusions Biomarkers have permitted to estimate prevalence of advanced fibrosis around 2.8% in a general population aged 40 years or older, and several risk factors which may be used for the validation of selective or non-selective screening strategies.